CRISPR/methotrexate-integrated strategy for TCR-T cell engineering with reduced chromosome 14 loss

Q: What does this research mean for the field?

A CRISPR/methotrexate-integrated strategy for TCR-T cell engineering mitigates viral vector risks and reduces CRISPR-associated genomic instability, providing a GMP-compatible approach for safer adoptive immunotherapies. Novelty: ClaimNovelty.METHODOLOGICAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

Jian Xu; Lianghua Shen; Ziyu Chen; Changmeng Zhang; Xiaodan Ding; Qiaomei He; Xiaofeng Zhou; Peiyao Jiang; Jiayu Liu; L. Li; Jinan Fang; Fanlin Li; Liping Wan; Xueying Ding; Yuqin Yang; Xiaorui Wang; Pengran Wang; Xianmin Song; Yan Zhang

doi:10.1016/j.omtm.2025.101635

Abstract

and in xenograft models. In conclusion, this integrated platform mitigates viral vector risks, alleviates concerns of CRISPR-associated genomic instability, and provides a good manufacturing practice (GMP)-compatible approach that may facilitate the development of safer adoptive TCR-T immunotherapies.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Xu et al. (2025) studied this question.

synapsesocial.com/papers/6a22fc5e6e4b7ecdd5f72a3e https://doi.org/10.1016/j.omtm.2025.101635

View Full Paper

Ask AI

Bookmark

Share

CRISPR/methotrexate-integrated strategy for TCR-T cell engineering with reduced chromosome 14 loss

Abstract

Discussion

Cite This Study

CRISPR/methotrexate-integrated strategy for TCR-T cell engineering with reduced chromosome 14 loss

Abstract

Discussion

Cite This Study

Keep reading

Keep reading